Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in radiation-induced brain injury
NCT03208413Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thalidomide in Radiation-Induced Brain Injury (RIBI), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Brain injury remission at 15 weeks. Status: unknown.
02
Drugs
thalidomide
03
Conditions
Radiation-Induced Brain Injury (RIBI)
Beyond the preview
Go deeper on NCT03208413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208413.